<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of the newly developed synthetic selective antithrombin agent MD-805 were examined in 11 patients with progressing <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo>, as an open trial </plain></SENT>
<SENT sid="1" pm="."><plain>Nine (82%) of 11 patients improved after 1 week of intravenous drip infusion </plain></SENT>
<SENT sid="2" pm="."><plain>No hemorrhagic complications were observed during the therapy </plain></SENT>
<SENT sid="3" pm="."><plain>These results suggest that MD-805 is a safe and effective agent for treatment of progressing <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> </plain></SENT>
</text></document>